ResearchMoz

Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

GBI Research
Published Date » 2014-08-21
No. Of Pages » N/A
 GBI Research, the leading business intelligence provider, has released its latest research: ‘Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM’, which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products. The value of the GBM market in the APAC region amounted to an estimated $49.4m in 2013, and is expected to register a...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Introduction
2.1 Disease Introduction
2.2 Classification of Brain Tumors
2.3 Tumor Grading
2.4 Subtypes of Glioblastoma Multiforme
2.5 Etiology
2.6 Pathophysiology
2.6.1 Loss of Heterozygosity of Chromosome 10
2.6.2 Epidermal Growth Factor Receptor Amplification
2.6.3 Phosphatase and Tensin Homolog Mutation
2.6.4 Loss of p53 Function
2.6.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function
2.6.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation
2.7 Symptoms
2.8 Diagnosis
2.9 Prognosis
2.10 Epidemiology
2.11 Treatment Options
2.11.1 Surgery
2.11.2 Radiation Therapy
2.11.3 Chemotherapy
2.11.4 Targeted Therapy
2.11.5 Drugs for Symptom Relief
2.11.6 Other Alternative Therapies
2.12 Treatment Algorithm
2.13 GBI Research Report Guidance

3 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products
3.1 Key Marketed Products
3.2 Temodar (temozolomide) – Merck
3.3 Avastin (bevacizumab) – Roche
3.4 BiCNU (carmustine) and Gliadel Wafer (carmustine in polifeprosan)
3.4.1 BiCNU (carmustine) – Bristol-Myers Squibb
3.4.2 Gliadel Wafer (carmustine in polifeprosan) – Eisai
3.5 Unlicensed/Off-Label Use in Glioblastoma Multiforme
3.5.1 Lomustine
3.5.2 Carboplatin
3.5.3 Teniposide
3.6 Comparative Efficacy and Safety
3.7 Unmet Needs

4 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Pipeline
4.1 Overall Pipeline
4.2 Molecular Targets
4.3 Clinical Trials
4.3.1 Clinical Trial Size
4.3.2 Clinical Trial Duration
4.3.3 Failure Rate of Developmental Pipeline
4.3.4 Summary of Clinical Trial and Risk Analysis
4.4 Promising Pipeline Candidates
4.4.1 Rindopepimut (CDX-110) – Celldex Therapeutics
4.4.2 Avastin (bevacizumab) – Roche
4.4.3 Cotara – Peregrine Pharmaceuticals
4.4.4 BIOMAb (nimotuzumab) – BioCon
4.5 Heat Map of Safety and Efficacy and Product Competitiveness Framework for Glioblastoma Multiforme Pipeline

5 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Market Forecast to 2020
5.1 Asia-Pacific Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 Australia
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 India
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Drivers and Barriers for the Glioblastoma Multiforme Therapeutics in the Asia-Pacific Market to 2020
5.6.1 Drivers
5.6.2 Barriers

6 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Deals and Strategic Consolidations
6.1 Major Co-Development Deals
6.1.1 Del Mar Pharmaceuticals Enters into Agreement with Guangxi Wuzhou Pharmaceutical
6.1.2 Immatics Biotechnologies Enters into Agreement with Cancer Research UK
6.2 Major Licensing Deals
6.2.1 Eisai Received Marketing Authorization Holder License with Nobelpharma for Gliadel in Japan
6.2.2 Teva Pharma Enters into Agreement with Perrigo for Generic Temozolomide
6.2.3 SOM Biotech Enters into Licensing Agreement with Argon Pharma for SOM0777
6.2.4 ImmunoCellular Therapeutics Enters into Agreement with University of Pennsylvania
6.2.5 Bexion Pharmaceuticals Enters into Agreement with Cincinnati Children’s Hospital Medical Center
6.2.6 Celldex Therapeutics Enters into Agreement with Duke University Brain Tumor Cancer Center

7 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Bibliography
7.4 All Pipeline Products by Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 Phase I
7.4.4 Phase II
7.4.5 Phase III and Pre-Registration
7.4.6 Undisclosed stage of development
7.5 Market Forecasts to 2020
7.5.1 Asia-Pacific
7.5.2 Australia
7.5.3 China
7.5.4 India
7.5.5 Japan
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Therapeutic Landscape
7.6.4 Forecasting
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Competitive Landscape
7.8 Expert Panel Validation
7.9 Contact Us
7.10 Disclaimer

List of Tables

Table 1: Glioblastoma Multiforme, Classification of Brain Tumors by the American Association of Neurological Surgeons, 2014
Table 2: Glioblastoma Multiforme, World Health Organization Classification of Glioma, 2005
Table 3: Glioblastoma Multiforme, Karnofsky Performance Status Score (%), 1984
Table 4: Discovery
Table 5: Preclinical and IND/CTA-filed
Table 6: Phase I
Table 7: Phase II
Table 8: Phase III and pre-registration
Table 9: Undisclosed stage of development
Table 10: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Forecast Data, 2013–2020
Table 11: Glioblastoma Multiforme Therapeutics, Australia, Forecast Data, 2013–2020
Table 12: Glioblastoma Multiforme Therapeutics, China, Forecast Data, 2013–2020
Table 13: Glioblastoma Multiforme Therapeutics, India, Forecast Data, 2013–2020
Table 14: Glioblastoma Multiforme Therapeutics, Japan, Forecast Data, 2013–2020

List of Figures

Figure 1: Glioblastoma Multiforme, Genetic Pathways to Primary and Secondary GBM and the Incidence of Mutations, 2014
Figure 2: Glioblastoma Multiforme, Treatment Algorithm for Glioblastoma Multiforme, 2014
Figure 3: Glioblastoma Multiforme, Treatment Options for Recurrent Glioblastoma Multiforme, 2014
Figure 4: Glioblastoma Multiforme, Global, Historical Sales of Temodar ($m), 2008–2013
Figure 5: Glioblastoma Multiforme, Global, Historical Sales of Avastin ($bn), 2004–2013
Figure 6: Glioblastoma Multiforme, Global, Historical Sales of Gliadel Wafer ($m), 2003–2006
Figure 7: Glioblastoma Multiforme , Global, Heat Map for Marketed Products, 2013
Figure 8: Glioblastoma Multiforme, Global, Overall Pipeline, 2013
Figure 9: Glioblastoma Multiforme, Global, Program Type by Phase and Molecular Targets, 2013
Figure 10: Glioblastoma Multiforme, Global, Mean Clinical Trial Size by Molecule Type, 2006–2013
Figure 11: Glioblastoma Multiforme, Global, Mean Clinical Trial Duration by Molecule Type (Months), 2006–2013
Figure 12: Glioblastoma Multiforme, Global, Clinical Trial Failure Rate by Phase by Molecule Type and Reasons for Failure, 2006–2013
Figure 13: Glioblastoma Multiforme, Asia-Pacific, Heat Map for Pipeline Products, 2013
Figure 14: Glioblastoma Multiforme, Asia-Pacific, Product Competitiveness Framework, 2013
Figure 15: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Treatment Use Patterns (‘000), 2013–2020
Figure 16: Glioblastoma Multiforme Therapeutics, Asia-Pacific, Market Size ($m), 2013–2020
Figure 17: Glioblastoma Multiforme Therapeutics, Australia, Treatment Use Patterns (‘000), 2013–2020
Figure 18: Glioblastoma Multiforme Therapeutics, Australia, Annual Cost of Therapy ($), 2013–2020
Figure 19: Glioblastoma Multiforme Therapeutics, Australia, Market Size ($m), 2013–2020
Figure 20: Glioblastoma Multiforme Therapeutics, China, Treatment Use Patterns (‘000), 2013–2020
Figure 21: Glioblastoma Multiforme Therapeutics, China, Annual Cost of Therapy ($), 2013–2020
Figure 22: Glioblastoma Multiforme Therapeutics, China, Market Size ($m), 2013–2020
Figure 23: Glioblastoma Multiforme Therapeutics, India, Treatment Use Patterns (‘000), 2013–2020
Figure 24: Glioblastoma Multiforme Therapeutics, India, Annual Cost of Therapy ($), 2013–2020
Figure 25: Glioblastoma Multiforme Therapeutics, India, Market Size ($m), 2013–2020
Figure 26: Glioblastoma Multiforme Therapeutics, Japan, Treatment Use Patterns (‘000), 2013–2020
Figure 27: Glioblastoma Multiforme Therapeutics, Japan, Annual Cost of Therapy ($), 2013–2020
Figure 28: Glioblastoma Multiforme Therapeutics, Japan, Market Size ($m), 2013–2020

Upcoming Reports:

Home Networking Device Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
A home network or home area network (HAN) is a residential local area network (LAN) for communication between digital devices typically deployed in the home, usually a small number of personal computers and accessories, such as printers and mobile computing devices. An important function is the sharing of Internet access, often a broadband service provisioned by fiber-to-the-home or via Cable Internet Access, Digital Subscriber Line (DSL) or mobile broadband by Internet service providers (ISPs). Home networking adoption continues to grow in all regions around the world, driven...
Greece: surface-active preparations market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the surface-active preparations market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the surface-active preparations market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Poland: quartz market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the quartz market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the quartz market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Illinois Voicing for Funds to Promote Clean Energy Plants
Mar 26, 2015  
The advocates of renewable energy has been voicing for overhaul of the Illinois’s clean energy law for several years in a row. Refurbishing the law would entail a release of over $100 million that was collected as ratepayer charges that they can invest on payment for new solar and wind projects. However, the proponents could not help the cause and now it seems that the state is...
Michigan To Capitalize on Clean and Local Energy
Mar 26, 2015  
For years now Americans have been campaigning to promote “eat locally and shop locally” culture. Inspired from the drive, Michiganders have got on board the plan to locally harness the energy to power their lives.  It will be very interesting to see how Gov. Rick Snyder’s vision of “no-regret energy future”, which has its key focus on curbing the...
Noble Energy Pulls Out from Ruth C License Exploration
Mar 26, 2015  
Citing issues related to “regulatory uncertainty”, in the energy and gas sector of Israel, the Houston-based company named Noble Energy forwent with its permit for operation in the Ruth C exploration license, as reported by Tel Aviv Stock Exchange on Thursday.  The Ruth C license zone is located off the Haifa coast, to the east of the larger Tamar basin. Energy reserve...
Leaders Go Back to School to Motive Students to Join the Construction Industry
Mar 26, 2015  
The housing sector is facing a major shortage in UK as the region suffers from lack of skilled construction workers. Amidst this crisis, two of the industry leaders are touring schools to encourage students to be a part of the industry which so desperately needs them. According to the Construction Industry Training Board, UK needs a workforce of 180,000 or more with adequate skill sets...
Israel Freezes Construction of 1,500 New Housing Units
Mar 26, 2015  
Israel has scrapped the plan to build 1,500 new housing units in East Jerusalem. The decision comes despite Prime Minister Benjamin Netanyahu's announcement to continue construction regardless of international pressure. East Jerusalem is the neighboring region of Har Homa, a little beyond the Green Line.  From the looks of it, the construction plan in Har Homa seems to have been...